Natural killer cell neoplasms

Cancer

Volumn 112, Issue 7, 2008, Pages 1425-1436

  Liang, Xiayuan ^a,b,d   Graham, Douglas K ^a,c  

^a CHILDREN S HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Nutrition Obesity Research Center at the University of Colorado   (United States)

^d CHILDREN S HOSPITAL COLORADO   (United States)

Author keywords

CD56; Natural killer cell; Natural killer cell leukemia; Natural killer cell lymphoma; Natural killer cell tumor

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEPSIPEPTIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; PREDNISOLONE; PREDNISONE; VINCRISTINE; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; B LYMPHOCYTE ACTIVATION; CANCER CYTODIAGNOSIS; CELL LINEAGE; CLINICAL FEATURE; CUTANEOUS T CELL LYMPHOMA; CYTOGENETICS; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HETEROZYGOSITY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LYMPHATIC LEUKEMIA; NATURAL KILLER T CELL; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TISSUE SECTION; WORLD HEALTH ORGANIZATION;

ANIMALS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; LYMPHOMA; NEOPLASM INVASIVENESS;

EID: 41149121184     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23316     Document Type: Review

References (103)

1. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood. 1995;85:2654-2670.
2. Lanier LL, Spits H, Phillips JH. The developmental relationship between NK cells and T cells. Immunol Today. 1992;13:392-395.
3. Sanchez MJ, Muench MO, Roncarolo MG, et al. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med. 1994;180:569-576.
4. Spits H, Blom B, Jaleco AC, et al. Early stages in the development of human T, natural killer and thymic dendritic cells. Immunol Rev. 1998;165:75-86.
5. Jaffe ES. Classification of natural killer (NK) cell and NK-like T cell malignancies. Blood. 1996;87:1207-1210.
6. DiGiuseppe JA, Louie DC, Williams JE, et al. Blastic natural killer cell leukemia/lymphoma: a clinicopathologic study. Am J Surg Pathol. 1997;21:1223-1230.
7. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood. 1997;89:4501-4514.
8. Siu LLP, Chan JKC, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17:539-554.
9. Chan JK, Wong KF, Jaffe ES, et al. Aggressive NK-cell leukemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW. eds. World Health Organization Classification of Tumours: Pathology and Genetics, Tumours of Hematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:198-200.
10. Chan JK, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics, Tumours of Hematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:204-207.
11. Chan JKC, Jaffe ES, Ralfkiaer E. Blastic NK-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW., eds. World Health Organization Classification of Tumours: Pathology and Genetics, Tumours of Hematopoietic and Lymphoid Tissue. Lyon, France: IARC Press; 2001:214-215.
12. Herling M, Teitell MA, Shen RR, et al. TCL 1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 2003;101:5007-5009.
13. Petrella T, Meijer C, Dalac S, et al. TCL1 and CLA expression in agranular CD4/CD56 hematodermic neoplasms (blastic NK-cell lymphomas and leukemia cutis. Am J Clin Pathol. 2004;122:307-313.
14. Chaperot L, Bendriss N, Manches O, et al. Identification of a leukemic counterpart of the plasmacytoid dendritic cells. Blood. 2001;97:3210-3217.
15. Jaffe ES, Chan JKC, Su IJ, et al. Report of the workshop on nasal and related extranodal angiocentric T/natural killer cell lymphomas. Am J Surg Pathol. 1996;20:103-111.
16. Sheibani K, Winberg CD, Burke JS, et al. Lymphoblastic lymphoma expressing natural killer cell-associated antigens: a clinicopathologic study of 6 cases. Leukemia Res. 1987;11:371-377.
17. Suzuki R, Nakamura S. Malignancies of natural killer (NK) cell precursor: myeloid/NK cell precursor acute leukemia and blastic NK cell lymphoma/leukemia. Leukemia Res. 1999;23:615-624.
18. Oshimi K. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol. 2003;78:18-23.
19. Suzuki R, Nakamura S, Suzumiya J, et al. Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer. 2005;104:1022-1031.
20. Lin CW, Liu TY, Chen SU, et al. CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005;106:3567-3574.
21. Graham DK, Liang X, Miller KL, et al. Disseminated nasopharyngeal natural killer cell lymphoblastic lymphoma in a child. Med Pediatr Oncol. 2003;40:251-253.
22. Adachi M, Maeda K, Takekawa M, et al. High expression of CD56 (N-CAM) in a patient with cutaneous CD4-positive lymphoma. Am J Hematol. 1994;47:278-282.
23. Brody JP, Allen S, Schulman P, et al. Acute agranular CD4-positive natural killer cell leukemia: comprehensive clinicopathologic studies including virologic and in vitro culture with inducing agents. Cancer. 1995;75:2474-2483.
24. Waski MA, Sackstein R, Novick, et al. Cutaneous CD56+ large T-cell lymphoma associated with high serum concentration of IL-2. Hum Pathol. 1996;27:738-744.
25. Dummer R, Potoczna N, Haffner AC, et al. A primary cutaneous non-T, non-B CD4+CD56+ lymphoma. Arch Dermatol. 1996;132:550-553.
26. Bastian BC, Ott G, Muller-Deubert S, et al. Primary cutaneous natural killer/T-cell lymphoma. Arch Dermatol. 1998;134:109-111.
27. Savoia P, Fierro MT, Novelli M, et al. CD56 positive cutaneous lymphoma: a poorly recognized entity in the spectrum of primary cutaneous disease. Br J Dermatol. 1997;137:966-971.
28. Falco RP, Garcia AB, Margues MG, et al. Blastic CD4 NK cell leukemia/lymphoma: a distinct clinical entity. Leukemia Res. 2002;26:803-807.
29. Child EJ, Mitchell TJ, Whittaker SJ, et al. Blastic natural killer cell and extranodal natural killer cell-like T-cell lymphoma presenting in the skin: report of 6 cases from the U.K. Br J Dermatol. 2003;148:507-515.
30. Chang SE, Choi HJ, Huh J, et al. A case of primary cutaneous CD56+, TdT+, CD4+, blastic NK-cell lymphoma in a 19-year-old woman. Am J Dermatopathol. 2002;24:72-75.
31. Penven K, Macro M, Salaun V, et al. Skin manifestations in CD4+, CD56+ malignancies. Eur J Dermatol. 2003;13:161-165.
32. Shapiro M, Wasik MA, Junkins-Hopkins JM, et al. Complete remission in advanced blastic NK-cell lymphoma/leukemia in elderly patients using hyper-CVAD regimen. Am J Hematol. 2003;74:46-51.
33. Mori KL, Egashira M, Oshimi K. Differentiation stage of natural killer cell-lineage lymphoproliferative disorders based non phenotypic analysis. Br J Haematol. 2001;115:225-228.
34. Kern WF, Spier CM, Miller TP, et al. NCAM (CD56)-positive malignant lymphoma. Leukemia Lymphoma. 1993;12:1-8.
35. Almasri NM, Mitchell D, Braylan RC. Blastic natural killer cell [letter]. Am J Surg Pathol. 1999;23:991-992.
36. Carayol G, Robin C, Bourhis JH, et al. NK cells differentiated from bone marrow, cord and peripheral blood stem cells exhibit similar phenotype and functions. Eur J Immunol. 1998;28:1991-2002.
37. Berardi AC, Meffre E, Pflumio F, et al. Individual CD34+CD38lowCD19-CD10- progenitor cells from human cord blood generate B lymphocytes and granulocytes. Blood. 1997;89:3554-3564.
38. + malignancies. Blood. 2002;99:1556-1563.
39. Petrella T, Comeau MR, Maynadie M, et al. "Agranular CD4+ CD56+ hematodermic neoplasm" (blastic NK-cell lymphoma) originated from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am J Surg Pathol. 2002;26:852-862.
40. Joye DL, Geigerman CM, Herling M, et al. The pattern of expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ blastoid tumors. Mod Pathol. 2006;19:1555-1562.
41. Facchetti F, Vermi W. Plasmacytoid monocytes and plasmacytoid dendritic cells: immune system cells linking innate and acquired immunity [in Italian]. Pathologica. 2002;94:163-175.
42. Herling M, Jones D. CD4+/CD56+ hematodermic tumor: the features of an evolving entity and its relationship to dendritic cells. Am J Clin Pathol. 2007;127:687-700.
43. Willemze R, Jeffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.
44. Liang X, Greffe B, Garrington T, Graham DK. Precursor natural killer cell leukemia. Pediar Blood Cancer. 2007 Apr 6 [Epub ahead of print].
45. Dubois SG, Etzell JE, Matthay KK, et al. Pediatric acute blastic natural killer cell leukemia. Leukemia Lymphoma. 2002;43:901-906.
46. Hyakuna N, Toguchi S, Higa T, et al. Childhood blastic NK cell leukemia successfully treated with L-asparaginase and allogeneic bone marrow transplantation. Pediatr Blood Cancer. 2004;42:631-634.
47. Matano S, Nakamura S, Nakamura S, et al. Monomorphic agranular natural killer cell lymphoma/leukemia with no Epstein-Barr virus association. Acta Haematol. 1999;101:206-208.
48. Tamura H, Ogata K, Mori S, et al. Lymphoblastic lymphoma of natural killer cell origin, presenting as pancreatic tumour. Histopathology. 1998;32:508-511.
49. Petrella T, Bagot M, Willemze R, et al. Blastic NK-cell lymphomas (agranular CD4+CD56+ hematodermic neoplasms). Am J Clin Pathol. 2005;123:662-675.
50. Chang C, Rodriguez A, Carreterro M, et al. Molecular characterization of human CD94: a type II membrane glycoprotein related to the C-type lectin superfamily. Eur J Immunol. 1995;9:2433-2437.
51. Lopez-Botet M, Perez-Villar JJ, Carreterro M, et al. Structure and function of the CD94 C-type lectin receptor complex involved in recognition of HLA class I molecules. Immmunol Rev. 1997;155:165-174.
52. - myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood. 1994;84:244-255.
53. Suzuki R, Yamamoto K, Seto M, et al. CD7+ and CD5+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood. 1997;90:2417-2428.
54. Nagai M, Bandoh S, Tasaka T, et al. Secondary myeloid/natural killer cell precursor acute leukemia following essential thrombocytopenia. Hum Pathol. 1999;30:868-871.
55. Inaba T, Shimazaki C, Sumikuma T, et al. Clinicopathological features of myeloid/natural killer (NK) cell precursor acute leukemia. Leukemia Res. 2001;25:109-113.
56. Handa H, Motohashi S, Isozumi K, et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside. Acta Haematol. 2002;108:47-52.
57. Ikewaki J, Otsuka E, Satou J, et al. Myeloid/natural killer cell precursor acute leukemia with minor bcr/abl mRNA transcript. Br J Haematol. 2002;118:684-685.
58. Tezuka K, Nakayama H, Honda K, et al. Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation. Int J Hematol. 2002;75:201-206.
59. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994;8:823-826.
60. Suzuki R, Murata M, Kami M, et al. Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0. Int J Hematol. 2003;77:482-489.
61. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia. 2005;19:2186-2194.
62. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998;16:70-77.
63. Cuadra-Garcia I, Proulx GM, Wu CL, et al. Sinonasal lymphoma: a clinicopathologic analysis of 58 cases from the Massachusetts General Hospital. Am J Surg Pathol. 1999;23:1356-1369.
64. Gaal K, Sun NC, Hernandez AM, et al. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol. 2000;24:1511-1517.
65. Kim CE, Cho JH, Yang WI, et al. Angiocentric lymphoma of the head and neck: patterns of systemic failure after radiation treatment. J Clin Oncol. 2000;18:54-63.
66. Chim CS, Ma SY, Au WY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2004;103:216-221.
67. Davison SP, Habermann TM, Strickler JG, et al. Nasal and nasopharyngeal lymphomas. Laryngoscope. 1996;106:139-143.
68. Imamura N, Kisunoki Y, Kajihara H, et al. Aggressive natural killer cell leukemia/lymphoma with N901-positive surface phenotype: evidence for the existence of a third lineage in lymphoid cells. Acta Hematol. 1988;80:121-128.
69. Imamura N, Kisunoki Y, Kawa-Ha K, et al. Aggressive natural killer cell leukemia/lymphoma: report of 4 cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Hematol. 1990;75:49-59.
70. Kwong YL, Chan AC, Liang R, et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol. 1997;97:821-829.
71. Mori N, Yamashita Y, Tsuzuki T, et al. Lymphomatous features of aggressive NK cell leukaemia/lymphoma with massive necrosis, haemophagocytosis and EB virus infection. Histopathology. 2000;37:363-371.
72. Yatabe Y, Mori N, Hirabayashi N, et al. Natural killer cell leukemia, an autopsy case. Arch Pathol Lab Med. 1994;118:1201-1204.
73. Quintanilla-Martinez L, Jaffe ES. Aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies. Histopathology. 2000;37:372-374.
74. Oshimi K, Yamada O, Kaneko T, et al. Laboratory findings and clinical courses of patients with granular lymphocyte-proliferative disorders. Leukemia. 1993;7:782-788.
75. Tefferi A, Li C-Y, Witzig TE, et al. Chronic natural killer cell lymphocytosis: a descriptive clinical study. Blood. 1994;84:2721-2725.
76. Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2004;41:277-284.
77. Tefferi A. Chronic natural killer cell lymphocytosis. Leuk Lymphoma. 1996;20:245-248.
78. Ryder J, Wang X, Bao L, et al. Aggressive natural killer cell leukemia: report of a Chinese series and review the literature. Int J Hematol. 2007;85:18-25.
79. Oshimi K, Kawa K, Nakamura S, et al. NK-cell neoplasms in Japan. Hematology. 2005;10:237-245.
80. Weiss LM, Arber DA, Strickler JG. Nasal T-cell lymphoma. Ann Oncol. 1994;5(suppl 1):S39-S42.
81. Tao Q, Ho FCS, Loke SL, et al. Epstein-Barr virus is localized in the tumor cells of nasal lymphomas of NK, T or B cell types. Int J Cancer. 1995;60:315-320.
82. Medeiros LJ, Peiper SC, Elwood L, et al. Angiocentric immunoproliferative lesions: a molecular analysis of 8 cases. Hum Pathol. 1991;22:1150-1157.
83. Minarovits J, Hu LF, Imai S, et al. Clonality, expression and methylation patterns of the EBV genomes in lethal midline granulomas classified as peripheral angiocentric T-cell lymphomas. J Gen Virol. 1994;75:77-84.
84. Wong KF, Zhang YM, Chan JKC. Cytogenetic abnormalities in natural killer cell lymphoma/leukemia: Is there a consistent pattern? Leuk Lymphoma. 1999;34:241-250.
85. Zhang Y, Matthiesen P, Harder S, et al. A 3-cM commonly deleted region in 6q21 in leukemias and lymphomas delineated by fluorescence in situ hybridization. Genes Chromosomes Cancer. 2000;27:52-58.
86. Sun HS, Su IJ, Lin YC, et al. A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma. Br J Haematol. 2003;122:590-599.
87. Siu LL, Wong KF, Chan JK, et al. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent pattern of genetic alterations. Am J Pathol. 1999;155:1419-1425.
88. Siu LL, Chan V, Chan JK, et al. Consistent patterns of allelic loss in natural killer cell lymphoma. Am J Pathol. 2000;157:1803-1809.
89. Sakata K, Hareyama M, Ohuchi A, et al. Treatment of lethal midline granuloma type nasal T-cell lymphoma. Acta Oncol. 1997;36:307-311.
90. Koom WS, Chung EJ, Yang WI, et al. Angiocentric T-cell and NK/T-cell lymphomas: radiotherapeutic viewpoints. Int J Radiat Oncol Biol Phys. 2004;59:1127-1137.
91. Robbins KT, Fuller LM, Vlasak M, et al. Primary lymphomas of the nasal cavity and paranasal sinuses. Cancer. 1985;56:814-819.
92. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphoma/leukemias. Semin Hematol. 2003;40:221-232.
93. Cheung MM, Chan KF, Lau WH, et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int Radiat Oncol Biol Phys. 2002;54:182-190.
94. You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol. 2004;15:618-625.
95. Ribrag V, EU Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia. 2001;15:1123-1126.
96. Li CC, Tien HF, Tang JL, et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer. 2004;100:366-375.
97. Kern WF, Spier CM, Hanneman EH, et al. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with propensity for unusual sites of involvement. Blood. 1992;79:2432-2437.
98. Ebihara Y, Manabe A. Tanaka R, et al. Successful treatment of natural killer (NK) cell leukemia following a long-standing chronic active Epstein-Barr virus (CAEBV) infection with allogeneic bone marrow transplantation. Bone Marrow Transplant. 2003;31:1169-1171.
99. Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant. 2003;31:105-111.
100. Kwong YL, Chan AL, Liang RHS. Natural killer cell lymphoma/leukemia: pathology and treatment. Hematol Oncol. 1997;15:71-79.
101. Greer JP. Therapy of peripheral T/NK neoplasms. Hematol Am Soc Hematol Educ Program. 2006;:331-337.
102. Piekarz RL, Robey R, Sandor V, et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood. 2001;98:2865-2868.
103. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109:31-39. Erratum in: Blood. 2007;109:5086.